ROTAPRO Rotational Atherectomy System
Boston Scientific Corp · Decision date Oct 21, 2026
What did the FDA decide?
The FDA recorded a 30-day notice decision, coded OK30, dated 2026-10-21 for supplement P900056/S229 to Boston Scientific Corp's ROTAPRO Rotational Atherectomy System, a coronary atherectomy catheter under product code MCX in the Cardiovascular specialty. The recorded supplement reason is a process change affecting a manufacturer, sterilizer, packager or supplier.
The stated scope is approval of changes to printed circuit board assembly (PCBA) soldering and strain relief fixtures for the system. This is a supplement-level decision on manufacturing fixtures, not a new approval of the whole device, and the source record gives no detail on the fixture changes, their validation or any effect on finished-device performance. No supporting documents were included, so the basis for the decision cannot be checked from this record alone.
FDA approval order statement
approval for changes to PCBA soldering and strain relief fixtures for ROTAPRO Rotational Atherectomy System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 21, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P900056/S229
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- Decision code
- OK30
- Decision date
- Oct 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: CATHETER, CORONARY, ATHERECTOMY.
- Applicant
- Boston Scientific Corp
- Product code
- MCX
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.
FDA decision timeline
P900056 · Original PMA
ROTABLATOR(R)
P900056/S229 received
Application receipt date recorded by FDA.
P900056/S228 · Related supplement
ROTAPRO Rotational Atherectomy System
P900056/S226 · Related supplement
ROTAPRO Rotational Atherectomy Systems
P900056/S229 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P900056
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ROTABLATOR(R)P900056 | Boston Scientific Corp | PMA approval | May 28, 1993 | FDA |
ROTAPRO Rotational Atherectomy SystemP900056/S228 | Boston Scientific Corp | PMA supplement | Oct 20, 2026 | FDA |
ROTAPRO Rotational Atherectomy SystemsP900056/S226 | Boston Scientific Corp | PMA supplement | Oct 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- Two Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P900056/S229
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

